Akebia Therapeutics Initiates Phase 2 Trial of Praliciguat for Rare Kidney Disease FSGS
核心洞察
Akebia Therapeutics has dosed the first patient in a Phase 2 clinical trial evaluating praliciguat, an oral soluble guanylate cyclase (搜索) stimulator, for treating focal segmental glomerulosclerosis (搜索) (FSGS (搜索)).
The randomized, double-blind, placebo-controlled study will enroll approximately 60 patients with biopsy-confirmed FSGS (搜索) to assess changes in urine protein-to-creatinine ratio over 24 weeks.
FSGS (搜索) affects approximately 40,000 patients in the U.S. with no currently approved treatments, representing a significant unmet medical need.
Akebia Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial evaluating praliciguat for the treatment of focal segmental glomerulosclerosis (搜索) (FSGS (搜索)), a rare kidney disease (搜索) affecting approximately 40,000 patients in the United States. The oral, once-daily soluble guanylate cyclase (搜索) (sGC) stimulator represents a potential breakthrough for a condition with no currently approved treatments.
"We are pleased by the timely initiation of this important Phase 2 clinical trial of praliciguat and have successfully dosed the first patient following the defined screening process," said Dr. Steven K. Burke, Chief Medical Officer at Akebia Therapeutics. "FSGS (搜索) is a rare kidney disease (搜索) that affects approximately 40,000 patients in the U.S, and there are no approved treatments."
Study Design and Endpoints
The Phase 2, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed FSGS (搜索). Approximately 60 patients who are already receiving maximally tolerated doses of an angiotensin-converting enzyme inhibitor (搜索) (ACEi) or an angiotensin receptor blocker (ARB) will be randomized 1:1 to receive praliciguat or placebo for an initial 24-week treatment period.
Following the double-blind period, all participants will receive praliciguat in an open-label portion of the study for an additional 24 weeks. The primary endpoint is defined as change from baseline in urine protein-to-creatinine ratio (UPCR) measured at Week 24, a widely-accepted endpoint measuring risk reduction of kidney failure. The secondary endpoint is defined as the percentage of patients with partial remission at Week 24, measured as a 40% UPCR reduction and UPCR less than 1.5 gram/gram.
Safety Profile and Development History
Akebia licensed praliciguat from Cyclerion Therapeutics, Inc. The compound has demonstrated a favorable safety profile in previous clinical studies. No significant safety issues were observed with praliciguat in Phase 1 studies in healthy volunteers and Phase 2 studies in heart failure (搜索) and diabetic kidney disease (搜索). Praliciguat adverse events were infrequent and consistent with its known blood pressure lowering effect.
"Praliciguat is a promising therapeutic candidate with no significant safety issues observed in Phase 1 studies in healthy volunteers and Phase 2 studies in heart failure (搜索) and diabetic kidney disease (搜索)," Burke noted. "Praliciguat is a key component of our recently announced mid-stage rare kidney disease (搜索) pipeline."
Future Development Plans
The company has indicated plans to assess praliciguat's use in other rare podocytopathies in the future, potentially expanding the therapeutic applications of this sGC stimulator beyond FSGS (搜索). This broader development strategy reflects Akebia's focus on addressing unmet medical needs in rare kidney diseases.